Can I get retatrutide by prescription?

No. Retatrutide is investigational and is not FDA-approved. In the United States, legitimate access is through enrollment in a clinical trial, or — for a small number of people with severe, complicated obesity who have failed approved therapy — through Eli Lilly's physician-initiated expanded access program. Neither is a retail prescription or a compounded prescription.

Retatrutide Is Not Compoundable: Legal Status, Trial Access, and Research Vendors

Q: Is there any way to get retatrutide outside a clinical trial?

Only through expanded access. Eli Lilly runs an individual-patient expanded access program (ClinicalTrials.gov NCT07629401) for adults with a BMI of 35 or higher plus two or more serious obesity-related complications who have failed maximum-dose approved therapy and cannot enroll in a trial. A treating physician must request it on the patient's behalf; patients cannot apply directly and access is not guaranteed.

Q: Are research-use retatrutide vendors equivalent to clinical trial access?

No. Research-use vendors are not equivalent to FDA-approved drugs, compounded prescriptions, or clinical trial supply. FDA has warned about unapproved GLP-1 products falsely labeled for research purposes or not for human consumption.

The short answer is no: retatrutide is not compoundable in the United States. FDA says retatrutide "cannot be used in compounding under federal law" and adds that it is not a component of an FDA-approved drug and has not been found safe and effective for any condition.^[1]

That is a stronger statement than "not available yet." It means a pharmacy cannot make a patient prescription for retatrutide just because a prescriber writes one, and a website selling "research retatrutide" is not the same thing as a legitimate trial or pharmacy supply chain.

Peptide Garden is an educational resource, not a medical or legal provider. This guide summarizes public FDA and ClinicalTrials.gov sources for informational purposes.

Quick facts

FDA approval: Not approved
U.S. compounding status: Cannot be compounded
Legitimate access today: Clinical trial, or expanded access (narrow)
Research vendors: Not equivalent to legal access

Why retatrutide is not compoundable

Compounding law is narrower than many peptide forums make it sound. FDA's bulk-substance framework separates traditional 503A pharmacies from 503B outsourcing facilities, but both pathways have limits.^[2]

For a 503A pharmacy, a bulk drug substance generally must fit one of these pathways:

It complies with an applicable USP or National Formulary monograph.
It is a component of an FDA-approved drug product when no monograph exists.
It appears on FDA's 503A bulks list.

For a 503B outsourcing facility, the substance generally must either appear on FDA's 503B clinical-need bulks list or be used to compound a drug product that appears on FDA's drug shortage list at the time of compounding, distribution, and dispensing.^[2]

Retatrutide does not fit those routes. FDA's GLP-1 safety page states the practical result plainly: retatrutide cannot be used in compounding under federal law.^[1]

Why this differs from semaglutide and tirzepatide

Semaglutide and tirzepatide are FDA-approved active ingredients in marketed drugs. Their compounding disputes have centered on shortage status, patient-specific need, bulk-substance policy, and copies of commercially available drugs.

Retatrutide is different. It is still investigational. There is no FDA-approved retatrutide drug product, no retail prescription version, and no lawful shortage-based copy of an approved retatrutide product. That is why "my clinic can prescribe compounded retatrutide" is a red flag rather than a normal access pathway.

Branded semaglutide or tirzepatide

FDA-approved prescription drugs. Compounding questions are sometimes disputed under limited rules tied to shortages, copies, and patient-specific need.

Retatrutide

Not FDA-approved and not compoundable. Legitimate access is through clinical trial enrollment, or a narrow physician-initiated expanded access program.

"Research retatrutide" vial

Not a pharmacy compound, not a prescription medication, and not equivalent to clinical trial supply.

Clinical trial access

Retatrutide is being studied in Eli Lilly's Phase 3 program under the development code LY3437943. ClinicalTrials.gov lists retatrutide studies in obesity, overweight, type 2 diabetes, chronic low back pain, osteoarthritis, obstructive sleep apnea, and related cardiometabolic indications.^[4]^[5]^[6]

Clinical trial access is not the same as shopping for a medication. A trial has eligibility criteria, informed consent, protocol visits, monitoring, randomization, and a sponsor-controlled investigational supply. Some participants may receive placebo. Some sites may be active but not recruiting, and some trials may have no nearby location.

If someone wants legitimate retatrutide access today, the practical path is to search ClinicalTrials.gov for "retatrutide" or "LY3437943" and contact listed study sites. A clinic, spa, or online vendor offering immediate paid access is not offering the same thing.

The other legitimate route: expanded access

Trials are not the only lawful path, and this is the part most coverage leaves out. Eli Lilly has an open expanded access program for retatrutide — the mechanism sometimes called "compassionate use." It is listed on ClinicalTrials.gov with a status of available.^[7]

Expanded access exists so that people with a serious condition and no remaining approved options can receive an investigational drug outside a trial. It is deliberately narrow. For retatrutide, the listed criteria are adults with:

a BMI of 35 kg/m² or higher, plus
two or more serious obesity-related complications, who have
already failed maximum-dose approved therapy, and who
cannot enroll in a retatrutide clinical trial.

How it actually works

A patient cannot apply. A treating physician has to request access on the patient's behalf through Lilly's medical information channel (the Lilly Answers Center), and Lilly decides case by case. There is no waiting list to join and no application form to fill in yourself. If this sounds like it might apply to you, the step is a conversation with the doctor who manages your care — not a website.

Two honest caveats. First, meeting the criteria does not mean access will be granted; single-patient expanded access is granted at the company's discretion and requires FDA and institutional review board sign-off as well. Second, this is genuinely a route for a small number of people with severe, complicated obesity — it is not a shortcut around the wait for approval, and it should not be read as one.

We mention it because it is real, it is free to ask about, and it is the honest alternative to a gray-market vial. If a person's situation is serious enough that they are considering buying unregulated retatrutide online, that same situation is exactly the one expanded access was designed for — and the conversation with their doctor is worth having first.

Why "research" vendors are not equivalent

The "research use only" label can make a product look official, but it does not turn an unapproved vial into a medication.

FDA has warned companies that sold unapproved GLP-1 products containing semaglutide, tirzepatide, or retatrutide while labeling them "for research purposes" or "not for human consumption." FDA says these products have been sold directly to consumers for human use with dosing instructions, are of unknown quality, and may be harmful.^[1]

That matters because research vendors are not equivalent to any of these:

FDA-approved manufacturers: no approved retatrutide product exists.
Licensed compounding pharmacies: retatrutide cannot be used in compounding under federal law.
Clinical trial supply: trial drug is controlled under a protocol with sponsor oversight, monitoring, and reporting.
Expanded access supply: also sponsor-controlled, physician-requested, and subject to FDA and ethics-board review.^[7]
Generic drugs: generics require FDA approval and therapeutic-equivalence review; retatrutide has neither.

FDA also emphasizes that even lawful compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.^[3] Research-use vendor products sit outside even that pharmacy framework.

If a provider offers "compounded retatrutide"

Treat the offer as a regulatory warning sign. Useful questions are:

Is the product being dispensed by a state-licensed pharmacy or FDA-registered 503B outsourcing facility?
What is the legal basis for compounding a substance FDA says cannot be used in compounding?
Is the product labeled as a patient prescription, an office-use product, or "research use only"?
Is the provider claiming FDA approval, generic equivalence, or pharmacy compounding status?

If the answer depends on "research use only," "not for human consumption," "not technically a prescription," or "the law is a gray area," that is not the same as legal retatrutide access.

FAQ

Is retatrutide compoundable?

No. FDA states that retatrutide cannot be used in compounding under federal law.^[1]

Can a 503A or 503B pharmacy make retatrutide?

FDA's current public position is no. The general 503A and 503B bulk-substance pathways are limited, and FDA specifically identifies retatrutide as a GLP-1 drug that cannot be used in compounding.^[1]^[2]

Can I buy retatrutide for research?

You may see vendors advertising it, but that is not equivalent to a medication, prescription, compounded product, or clinical trial supply. FDA has warned about unapproved GLP-1 products sold under "research purposes" or "not for human consumption" labels.^[1]

Is there any way to get retatrutide outside a trial?

For most people, no. There is one exception: Lilly runs an individual-patient expanded access program for adults with a BMI of 35 or higher plus two or more serious obesity-related complications who have failed maximum-dose approved therapy and cannot enroll in a trial. A physician has to request it; a patient cannot apply directly, and approval is not guaranteed.^[7]

When will retatrutide be available?

Not before late 2027 at the earliest, and possibly later. Retatrutide is still investigational. In July 2026 Lilly said it plans to submit retatrutide to the FDA in the first quarter of 2027 — that is a statement about when the company intends to file, not a decision date. Nothing has been submitted, so the FDA has not set a target action date, and any source quoting one is guessing. Until approval, legitimate access is limited to clinical trial enrollment and the narrow expanded access route described above.

The regulatory landscape is moving fast

Get notified when new regulatory changes affect peptide access. We track the FDA, so you don't have to.

Peptide

Retatrutide Profile

Full evidence profile covering retatrutide's mechanism, Phase 2 and Phase 3 data, safety signals, and regulatory status.

News

Semaglutide Compounding Under Scrutiny

The GLP-1 compounding context around shortages, FDA scrutiny, and legal risk.